Eupraxia Pharmaceuticals (NASDAQ:EPRX) Releases Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01), Zacks reports.

Eupraxia Pharmaceuticals Trading Up 2.6%

EPRX traded up $0.19 on Tuesday, reaching $7.61. The stock had a trading volume of 114,678 shares, compared to its average volume of 207,401. Eupraxia Pharmaceuticals has a fifty-two week low of $3.67 and a fifty-two week high of $9.32. The firm has a 50-day moving average of $7.35 and a 200-day moving average of $7.25. The company has a market capitalization of $459.87 million, a price-to-earnings ratio of -7.39 and a beta of 1.19.

Get Eupraxia Pharmaceuticals alerts:

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of EPRX. Royal Bank of Canada increased its holdings in Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after purchasing an additional 59,683 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after purchasing an additional 16,017 shares in the last quarter. Bank of America Corp DE increased its holdings in Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares in the last quarter. UBS Group AG increased its holdings in Eupraxia Pharmaceuticals by 155.4% in the 3rd quarter. UBS Group AG now owns 95,756 shares of the company’s stock worth $565,000 after purchasing an additional 58,257 shares in the last quarter. Finally, Raymond James Financial Inc. increased its holdings in Eupraxia Pharmaceuticals by 173.3% in the 3rd quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock worth $197,000 after purchasing an additional 21,161 shares in the last quarter.

Analyst Upgrades and Downgrades

EPRX has been the subject of several recent analyst reports. Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. William Blair initiated coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating for the company. Cantor Fitzgerald upped their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Check Out Our Latest Report on Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

Read More

• Five stocks we like better than Eupraxia Pharmaceuticals
• Navy Catalyst Ignites Odysight’s Growth Engine
• AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
• Axon Surged After Earnings and Is Still Down Over 50% From Highs
• The Event That Could Redefine Apple’s Summer Rally

Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.